{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T17:01:23Z","timestamp":1795194083391,"version":"4.10.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fujian Medical University Enlightenment Fund","award":["2023QH021"],"award-info":[{"award-number":["2023QH021"]}],"id":[{"id":"https:\/\/ror.org\/050s6ns64","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program","doi-asserted-by":"crossref","award":["2021-76"],"award-info":[{"award-number":["2021-76"]}],"id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fujian Provincial Clinical Research Center for Hematological Malignancies","award":["2020Y2006"],"award-info":[{"award-number":["2020Y2006"]}]},{"name":"Fujian Provincial Natural Science Foundation of China","award":["2021 J01743"],"award-info":[{"award-number":["2021 J01743"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00277-025-06528-2","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T04:45:04Z","timestamp":1754973904000},"page":"4093-4099","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical characteristics and outcome of pediatric patients with high-risk acute promyelocytic leukemia, with special focus on risk factors of early death"],"prefix":"10.1007","volume":"104","author":[{"given":"Qinli","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3389-5360","authenticated-orcid":false,"given":"Nainong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3233-351X","authenticated-orcid":false,"given":"Cai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"issue":"4","key":"6528_CR1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"issue":"15","key":"6528_CR2","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","volume":"133","author":"MA Sanz","year":"2019","unstructured":"Sanz MA, Fenaux P, Tallman MS et al (2019) Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood 133(15):1630\u20131643. https:\/\/doi.org\/10.1182\/blood-2019-01-894980","journal-title":"Blood"},{"issue":"4","key":"6528_CR3","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1182\/blood.V96.4.1247","volume":"96","author":"MA Sanz","year":"2000","unstructured":"Sanz MA, Lo Coco F, Mart\u00edn G et al (2000) Definition of relapse risk and role of Nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96(4):1247\u20131253. https:\/\/doi.org\/10.1182\/blood.V96.4.1247","journal-title":"Blood"},{"issue":"2","key":"6528_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/ped.12865","volume":"58","author":"T Taga","year":"2016","unstructured":"Taga T, Tomizawa D, Takahashi H (2016) Acute myeloid leukemia in children: current status and future directions. Pediatr Int 58(2):71\u201380. https:\/\/doi.org\/10.1111\/ped.12865","journal-title":"Pediatr Int"},{"issue":"26","key":"6528_CR5","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1200\/JCO.2016.71.6183","volume":"35","author":"MA Kutny","year":"2017","unstructured":"Kutny MA, Alonzo TA, Gerbing RB et al (2017) Arsenic trioxide consolidation allows anthracycline dose reduction for pediatric patients with acute promyelocytic leukemia: report from the children\u2019s oncology group phase III historically controlled trial AAML0631. J Clin Oncol 35(26):3021\u20133029. https:\/\/doi.org\/10.1200\/JCO.2016.71.6183","journal-title":"J Clin Oncol"},{"key":"6528_CR6","unstructured":"National Health and Family Planning Commission of the People\u2019s Republic of China Clinical pathway for acute promyelocytic leukaemia in children: 2010 edition [EB\/OL](2014-04-28)[2018-08-02]. https:\/\/wenku.baidu.com\/view\/a66a7b62640e52ea-551810a6f524ccbff121caf6"},{"issue":"12","key":"6528_CR7","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/ajh.25271","volume":"93","author":"MH Yang","year":"2018","unstructured":"Yang MH, Wan WQ, Luo JS et al (2018) Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: interim results of the SCCLG-APL clinical study. Am J Hematol 93(12):1467\u20131473. https:\/\/doi.org\/10.1002\/ajh.25271","journal-title":"Am J Hematol"},{"issue":"4","key":"6528_CR8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1182\/blood-2018-03-836528","volume":"132","author":"AM Testi","year":"2018","unstructured":"Testi AM, Pession A, Diverio D et al (2018) Risk-adapted treatment of acute promyelocytic leukemia: results from the international consortium for childhood APL. Blood 132(4):405\u2013412. https:\/\/doi.org\/10.1182\/blood-2018-03-836528","journal-title":"Blood"},{"issue":"23","key":"6528_CR9","doi-asserted-by":"publisher","first-page":"5811","DOI":"10.1002\/cncr.27623","volume":"118","author":"Y Chen","year":"2012","unstructured":"Chen Y, Kantarjian H, Wang H et al (2012) Acute promyelocytic leukemia: a population-based study on incidence and survival in the united states, 1975\u20132008. Cancer 118(23):5811\u20135818. https:\/\/doi.org\/10.1002\/cncr.27623","journal-title":"Cancer"},{"key":"6528_CR10","doi-asserted-by":"crossref","unstructured":"Zhang L, Zhu X (2012) Epidemiology, diagnosis and treatment of acute promyelocytic leukemia in children: the experience in China. Mediterr J Hematol Infect Dis 4(1):e2012012. http:\/\/www.mjhid.org\/article\/view\/9082","DOI":"10.4084\/mjhid.2012.012"},{"key":"6528_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.762653","volume":"11","author":"HH Zhu","year":"2021","unstructured":"Zhu HH, Ma YF, Yu K et al (2021) Early death and survival of patients with acute promyelocytic leukemia in ATRA plus arsenic era: a population-based study. Front Oncol 11:762653. https:\/\/doi.org\/10.3389\/fonc.2021.762653","journal-title":"Front Oncol"},{"issue":"2","key":"6528_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ajh.24230","volume":"91","author":"JJ Castillo","year":"2016","unstructured":"Castillo JJ, Mulkey F, Geyer S et al (2016) Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: a pooled analysis from four CALGB (alliance) clinical trials. Am J Hematol 91(2):199\u2013204. https:\/\/doi.org\/10.1002\/ajh.24230","journal-title":"Am J Hematol"},{"issue":"6","key":"6528_CR13","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3324\/haematol.2019.223925","volume":"105","author":"L Mazzarella","year":"2020","unstructured":"Mazzarella L, Botteri E, Matthews A et al (2020) Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies and correlation with FLT3 mutations and polyunsaturated fatty acid metabolism. Haematologica 105(6):1559\u20131566. https:\/\/doi.org\/10.3324\/haematol.2019.223925","journal-title":"Haematologica"},{"issue":"6","key":"6528_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29613","volume":"69","author":"KL Laurie","year":"2022","unstructured":"Laurie KL, Lee P, Rademaker A et al (2022) Obesity in children with acute promyelocytic leukemia: what is its prevalence and prognostic significance? Pediatr Blood Cancer 69(6):e29613. https:\/\/doi.org\/10.1002\/pbc.29613","journal-title":"Pediatr Blood Cancer"},{"key":"6528_CR15","unstructured":"The State Council Information Office Holds Press Conference on the (2020) Report on Chinese Residents\u2019 Nutrition and Chronic Disease Status -News Release-China Government Website. Available at: https:\/\/www.gov.cn\/xinwen\/2020-12\/24\/content_5572983.htm"},{"issue":"Suppl 2","key":"6528_CR16","doi-asserted-by":"publisher","first-page":"S126","DOI":"10.1016\/j.htct.2022.09.1276","volume":"45","author":"CNM Breviglieri","year":"2023","unstructured":"Breviglieri CNM, de Almeida MTA, Neto GZ et al (2023) Acute promyelocytic leukemia in childhood and adolescence: treatment results of a modified AIDA protocol at a Brazilian center. Hematol Transfus Cell Ther 45(Suppl 2):S126\u2013S130. https:\/\/doi.org\/10.1016\/j.htct.2022.09.1276","journal-title":"Hematol Transfus Cell Ther"},{"issue":"7","key":"6528_CR17","doi-asserted-by":"publisher","first-page":"e641","DOI":"10.1097\/MPH.0000000000001601","volume":"42","author":"AC de Azevedo","year":"2020","unstructured":"de Azevedo AC, Matsuda E, Cervellini JY et al (2020) Early mortality in children and adolescents with acute promyelocytic leukemia: experience of the Boldrini children\u2019s center. J Pediatr Hematol Oncol 42(7):e641\u2013e646. https:\/\/doi.org\/10.1097\/MPH.0000000000001601","journal-title":"J Pediatr Hematol Oncol"},{"key":"6528_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fped.2020.00086","volume":"8","author":"M Czoga\u0142a","year":"2020","unstructured":"Czoga\u0142a M, Pawi\u0144ska-WaSikowska K, Ksia\u017bek T et al (2020) Treatment outcome and the genetic characteristics of acute promyelocytic leukemia in children in Poland from 2005 to 2018. Front Pediatr 8:86. https:\/\/doi.org\/10.3389\/fped.2020.00086","journal-title":"Front Pediatr"},{"issue":"2","key":"6528_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020642","volume":"22","author":"C Gurnari","year":"2021","unstructured":"Gurnari C, Voso MT, Girardi K et al (2021) Acute promyelocytic leukemia in children: a model of precision medicine and chemotherapy-free therapy. Int J Mol Sci 22(2):642. https:\/\/doi.org\/10.3390\/ijms22020642","journal-title":"Int J Mol Sci"},{"issue":"3","key":"6528_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27542","volume":"66","author":"MA Kutny","year":"2019","unstructured":"Kutny MA, Geyer S, Laumann KM et al (2019) Outcome for pediatric acute promyelocytic leukemia patients at Children\u2019s Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance). Pediatr Blood Cancer 66(3):e27542. https:\/\/doi.org\/10.1002\/pbc.27542","journal-title":"Pediatr Blood Cancer"},{"key":"6528_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2019.102351","volume":"79","author":"W Hou","year":"2019","unstructured":"Hou W, Zhang Y, Jin B et al (2019) Factors affecting thrombohemorrhagic early death in patients with acute promyelocytic leukemia treated with arsenic trioxide alone. Blood Cells Mol Dis 79:102351. https:\/\/doi.org\/10.1016\/j.bcmd.2019.102351","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"6528_CR22","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1016\/j.clml.2018.08.001","volume":"19","author":"J Sun","year":"2019","unstructured":"Sun J, Zhu J, Zhou D et al (2019) Factors affecting early death and survival of patients with acute promyelocytic leukemia treated with ATRA-based therapy regimens. Clin Lymphoma Myeloma Leuk 19(1):e63\u2013e70. https:\/\/doi.org\/10.1016\/j.clml.2018.08.001","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"6528_CR23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.6004\/jnccn.2019.7351","volume":"18","author":"GS Guru Murthy","year":"2020","unstructured":"Guru Murthy GS, Szabo A, Michaelis L et al (2020) Improving outcomes of acute promyelocytic leukemia in the current era: analysis of the SEER database. J Natl Compr Canc Netw 18(2):169\u2013175. https:\/\/doi.org\/10.6004\/jnccn.2019.7351","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"6528_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12885-022-10499-2","volume":"23","author":"J Wen","year":"2023","unstructured":"Wen J, Xu F, Zhou Q et al (2023) Effects of peripheral blood leukocyte count and tumor necrosis factor-alpha on early death in acute promyelocytic leukemia. BMC Cancer 23(1):27. https:\/\/doi.org\/10.1186\/s12885-022-10499-2","journal-title":"BMC Cancer"},{"issue":"11","key":"6528_CR25","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1089\/dna.2019.4926","volume":"38","author":"J Zhou","year":"2019","unstructured":"Zhou J, Gou H, Zhang L et al (2019) ARID5B genetic polymorphisms contribute to the susceptibility and prognosis of male acute promyelocytic leukemia. DNA Cell Biol 38(11):1374\u20131386. https:\/\/doi.org\/10.1089\/dna.2019.4926","journal-title":"DNA Cell Biol"},{"issue":"8","key":"6528_CR26","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1080\/10428194.2021.1894651","volume":"62","author":"P Dhakal","year":"2021","unstructured":"Dhakal P, Lyden E, Rajasurya V et al (2021) Early mortality and overall survival in acute promyelocytic leukemia: do real-world data match results of the clinical trials? Leuk Lymphoma 62(8):1949\u20131957. https:\/\/doi.org\/10.1080\/10428194.2021.1894651","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"6528_CR27","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1007\/s12094-021-02625-6","volume":"23","author":"X Chen","year":"2021","unstructured":"Chen X, Fan S, Zhao Y, Zhou J (2021) Gene mutations in acute promyelocytic leukemia early death in patients treated with arsenic trioxide alone. Clin Transl Oncol 23(10):2171\u20132180. https:\/\/doi.org\/10.1007\/s12094-021-02625-6","journal-title":"Clin Transl Oncol"},{"key":"6528_CR28","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.2147\/CMAR.S297421","volume":"13","author":"YH Song","year":"2021","unstructured":"Song YH, Peng P, Qiao C et al (2021) Potential effects of the FLT3-ITD mutation on chemotherapy response and prognosis of acute promyelocytic leukemia. Cancer Manag Res 2371\u20132378. https:\/\/doi.org\/10.2147\/CMAR.S297421","journal-title":"Cancer Manag Res"},{"issue":"7","key":"6528_CR29","doi-asserted-by":"publisher","first-page":"e964","DOI":"10.1002\/ctm2.964","volume":"12","author":"JY Sung","year":"2022","unstructured":"Sung JY, Yun W, Kim HY et al (2022) Metabolic subtype reveals potential therapeutic vulnerability in acute promyelocytic leukaemia. Clin Transl Med 12(7):e964. https:\/\/doi.org\/10.1002\/ctm2.964","journal-title":"Clin Transl Med"},{"issue":"1","key":"6528_CR30","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/s41467-024-45737-7","volume":"15","author":"W Jin","year":"2024","unstructured":"Jin W, Dai Y, Chen L et al (2024) Cellular hierarchy insights reveal leukemic stem-like cells and early death risk in acute promyelocytic leukemia. Nat Commun 15(1):1423. https:\/\/doi.org\/10.1038\/s41467-024-45737-7","journal-title":"Nat Commun"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06528-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06528-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06528-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T07:48:51Z","timestamp":1757663331000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06528-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["6528"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06528-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"16 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Declarations"}},{"value":"The study was approved by the Ethics Committee of Fujian Medical University Union Hospital in accordance with the Declaration of Helsinki. After careful review, the committee granted a waiver of informed consent because the study used de-identified clinical data and involved no more than minimal risk to participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Yes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}